CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Other Events
Item8.01.
| Other Events. |
On April 5, 2017, CytoSorbents Corporation, a Delaware
corporation (the Company) completed its previously announced sale
of an aggregate of 2,222,222 shares of common stock to the
Company’s existing shelf registration statement (File No.
333-205806) on Form S-3. The Company received gross proceeds of
approximately $10,000,000, based on a public offering price of
$4.50 per share. After deducting the underwriting discounts and
commissions and estimated expenses related to the offering, the
Company received net proceeds of approximately $8,900,000. Cowen
and Company acted as the sole book-running manager and
representative of the underwriters for the offering. Aegis
Capital Corp, H.C. Wainwright Co., B. Riley Co., Maxim Group LLC
and Northland Capital Markets acted as co-managers for the
offering.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description. |
| 5.1 | Opinion of DLA Piper LLP (US). |
| 23.1 | Consent of DLA Piper LLP (US) (included in Exhibit 5.1). |
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Recent Trading Information
CYTOSORBENTS CORPORATION (NASDAQ:CTSO) closed its last trading session 00.00 at 4.50 with 132,304 shares trading hands.
